Introduction
============

Chronic hepatitis B (CHB) imposes a major health and economic burden as to 2 billion people worldwide have a history of hepatitis B virus (HBV) infection and \~360 million suffering from chronic HBV infection despite its declining incidence, leading the main cause of chronic diseases-related malfunction ([@b1-br-0-0-632],[@b2-br-0-0-632]). CHB may increase the risk of developing liver cirrhosis, severe liver failure and hepatocellular carcinoma, although primary HBV infections usually have a self-limited course in adults ([@b3-br-0-0-632]). Due to the residual virus and weakened immunity to reinfection, \~20% do not recover but progress to liver cirrhosis and 5% develop hepatocellular carcinoma through persistent infections ([@b3-br-0-0-632],[@b4-br-0-0-632]). However, the precise mechanisms leading to the chronicity of HBV infection remain to be elucidated at the molecular level. Infection may spread in a variety of ways including vertical (mother-to-child transmission) and horizontal transmission (lesions, bites, sanitary habits, sexual contact, medical exposure and drug use). In Asian countries, over half of the CHB patients were infected via vertical transmission and subsequently became HBV carriers ([@b5-br-0-0-632]). In adolescence, \~5% of the primary HBV carriers exhibit a long-term liver dysfunction and progress to chronic hepatitis ([@b6-br-0-0-632]). CHB significantly increases the probability of liver cirrhosis and primary hepatocellular cancer in the decades following the initial diagnosis and treatment ([@b7-br-0-0-632],[@b8-br-0-0-632]).

Currently, CHB remains a major concern regarding the issue of public health. However, the detailed pathogenesis of such a disease remains to be elucidated. In addition to the differences in the viral and environmental factors, the variations of host genetic factors are proved to dominate the pathological states of CHB development and progression. A number of genetic studies provide evidence that variations at the genetic level contribute to the development of chronic hepatitis ([@b9-br-0-0-632]--[@b11-br-0-0-632]). In addition to the aforementioned evidence, extensive epidemiological studies have shown that the variations of genetic factors, including cytokines ([@b12-br-0-0-632]--[@b14-br-0-0-632]), human leukocyte antigen (HLA) ([@b15-br-0-0-632]--[@b18-br-0-0-632]) and immune response-associated genes ([@b19-br-0-0-632]--[@b21-br-0-0-632]), could evidently affect the clinical outcomes of primary HBV infection. The HLA complex is the first discovered genetic factor exhibiting a definite correlation with HBV infection. HLA polymorphisms are usually associated with immune response variability. The genotype of the HLA genes may affect the progression or regression of HBV infection. The main function of HLA-II molecules is to present specific antigens to cluster of differentiation 4^+^ (CD4^+^) T cells, which regulate the immune response of CD8^+^ cytotoxic T lymphocytes (CTL) and are important to the production of specific-neutralizing antibodies. The process of HBV clearance is governed by eliminating infected cells via CTL and protecting additional cells from persistent infection via neutralizing antibody.

Therefore, it appears biologically viable to assume that variability in the interaction between HLA-II molecules and HBV antigens may be extremely important. This is verified by the evidence that patients with acute HBV infections showed superior HLA-II restricted CD4^+^ T-cell immune responses to the hepatitis B core antigen compared with chronic hepatitis patients ([@b22-br-0-0-632]). HLA class II gene polymorphisms are associated with various diseases, particularly for autoimmune disorders ([@b23-br-0-0-632]). However, the association of the HLA class II gene polymorphism with human diseases exhibits ethnical and geographic variability ([@b24-br-0-0-632]). Acute hepatitis B patients with strong HLA class I and II-restricted T-cell responses will not suffer from persistent HBV infection, while those without these responses may progress to CHB ([@b25-br-0-0-632]--[@b27-br-0-0-632]). Shi *et al* ([@b28-br-0-0-632]) indicated that HLA-II genes polymorphisms may be a crucial factor in affecting the outcome of HBV infection.

Kamatani *et al* ([@b29-br-0-0-632]) demonstrated that variants in the *HLA-DP* locus were strongly associated with CHB in the Asian population by conducting a genome-wide association study (GWAS). *HLA-DQB1* polymorphisms have recently been proved to affect immune responses of patients, and thus influence the clinical outcome of numerous diseases ([@b30-br-0-0-632],[@b31-br-0-0-632]). A previous GWAS study conducted by Mbarek *et al* ([@b32-br-0-0-632]) suggested that there was a strong association between the *HLA-DQB1* polymorphism (rs2856718) and CHB. *HLA-DQB1*\*0301 is also correlated with susceptibility to CHB ([@b33-br-0-0-632]--[@b35-br-0-0-632]), whereas *HLA-DQB1*\*0201 is proved to be a HBV-resistance gene in Xinjiang Uygur ([@b35-br-0-0-632]), and *HLA-DQB1*\*0501 has been revealed to be associated with persistent response to interferon treatment in chronic hepatitis C patients ([@b36-br-0-0-632]). Li *et al* ([@b37-br-0-0-632]) suggested that *HLA-DQB1*\*0302 could reduce the incidence of hepatocellular carcinoma by inhibiting the replication of HBV.

However, according to previous studies, it remains unclear whether *HLA-DQB1* polymorphisms are associated with the susceptibility to CHB due to small sample size and small phenotypic effects of *HLA-DQB1* locus. Therefore, the present study conducted a comprehensive meta-analysis to evaluate the potential association between *HLA-DQB1* polymorphisms and susceptibility to CHB. *HLA-DQB1* polymorphisms were quantitatively summarized in serum samples from patients with chronic hepatitis B infection. The case-control studies were adopted to evaluate whether *HLA-DQB1* polymorphisms are associated with the risk of chronic HBV infection by a comparison of the frequency distribution differences in 13 *HLA-DQB1* locus between the CHB and healthy control groups.

Materials and methods
=====================

### Search strategy and selection criteria

The PubMed, Embase, CNKI and Wanfang databases were searched for studies that reported on the association of *HLA-DQB1* polymorphisms with CHB between January 1, 1966 and July 30, 2015, using Medical Subject Heading terms 'major histocompatibility complex, class II, DQβ1' and 'polymorphisms' and 'chronic hepatitis B' or 'chronic hepatitis B infection' or 'chronic hepatitis' and corresponding free words. The Cochrane library (<http://www.cochrane.org>) was also searched using the term 'major histocompatibility complex, class II, DQβ1', 'polymorphisms' and 'chronic hepatitis B' or 'chronic hepatitis B infection'. Furthermore, the citations of the retrieved studies were reviewed in order to search for additional studies in association with the present meta-analysis. Included studies met the following criteria: i) Case-control studies, nested case-control studies or cohort studies; ii) studies investigating the correlation between *HLA-DQB1* polymorphisms and CHB, and the exposed risk factor should be *HLA-DQB1* polymorphisms; iii) relevant genotype frequencies, or odds ratio (OR) and 95% confidence interval (CI) should be reported; iv) full-text studies so that detailed information could be acquired. Excluded studies were: i) Studies without healthy control subjects; ii) duplicated publications; iii) studies that involved \<20 participants. When there was more than one study on the same subjects, only the most recent study was used.

### Data extraction

Data extraction was independently performed by two experienced investigators (J. Huang and Z. Zhou) and examined carefully by the other investigators. The concordance rate of the investigators was 95.6%. Disagreement was resolved by consensus. The following data was extracted from the included studies: The first author\'s name, date of publication, region, ethnicity, design method, genotyping, case and control subjects number, and genotype frequencies. Data were collected only for subjects whose *HLA-DQB1* polymorphisms status had been detected in CHB and its control.

### Assessment of study quality

Two investigators (J. Huang and Z. Zhou) independently assessed the quality of each included study according to a 12-point scoring system ([@b38-br-0-0-632]). Study design, number of cases, source of subjects, genotyping method and matching method of case and control were examined in the assessment of study quality. Studies, which met each of the following criteria (a prospective study, \>100 cases, including community-based participants, DNA sequencing was used to detect *HLA-DQB1* polymorphisms, and matched for age and gender), were scored on a 2-point scale. Studies with a total score of ≥8 were defined as high-quality studies, 5--7 were defined as medium-quality studies, and ≤4 were regard as low-quality studies. These cut-off values were confirmed based on the quality scores distribution of all studies. The Spearmans rank correlation coefficient of consensus between each of the two reviewers on the total quality assessment for all the associated studies was 0.97. In addition, disagreements were settled by consultation.

### Statistical analysis

The meta-analysis was performed using the software Stata 12.0 (Stata Corporation, College Station, TX, USA). OR and its corresponding 95% CI were adopted as the effect measures to conduct the meta-analysis. The Q-test, P-value and I^2^ test was used to evaluate heterogeneity among studies ([@b39-br-0-0-632],[@b40-br-0-0-632]). When the P-value of heterogeneity value was \>0.05 and I^2^\<50%, a fixed-effects model was adopted to calculate OR and its 95% CI, otherwise a random-effects model was used. The combined OR was calculated by two-sided Z-test, and P\<0.05 was considered to indicate a statistically significance difference. Sensitivity analysis was performed to assess the reliability and stability of the overall results. Publication bias test was performed using Begg\'s funnel plots and the Egger\'s regression plots ([@b41-br-0-0-632],[@b42-br-0-0-632]).

Results
=======

### Characteristics of eligible studies

Subsequent to searching the previously defined databases, a total of 13 studies were selected according to the established search strategy. Six studies that were not eligible, as shown by the data provided in the abstract and text, were excluded. Finally, a total of 7 case-control studies were available in this meta-analysis, including 815 CHB patients and 731 control subjects for *HLA-DQB1* polymorphisms ([@b34-br-0-0-632],[@b35-br-0-0-632],[@b37-br-0-0-632],[@b43-br-0-0-632]--[@b46-br-0-0-632]). The study search and selection process is shown in [Fig. 1](#f1-br-0-0-632){ref-type="fig"}. The detailed characteristics of the 7 included studies are shown in [Table I](#tI-br-0-0-632){ref-type="table"}. The publication year of the included studies ranged between 2003 and 2015. The distribution of the *HLA-DQB1* polymorphisms in CHB is shown in [Table II](#tII-br-0-0-632){ref-type="table"}. All the studies used blood samples for *HLA-DQB1* genotyping. All the quality scores of the included studies were \>7 (moderate-high quality) ([@b38-br-0-0-632]).

### Quantitative data synthesis

In conslusion, statistically significant pooled OR of *HLA-DQB1* polymorphisms were obtained for *HLA-DQB1* loci \[\*0201, case vs. control: I^2^=36.5%; P-value of heterogeneity=0.15; OR, 1.29; 95% CI, 1.02--1.64; P=0.0301 ([Fig. 2A](#f2-br-0-0-632){ref-type="fig"} and [Table III](#tIII-br-0-0-632){ref-type="table"}); \*0301, case vs. control: I^2^=0%; P-value of heterogeneity=0.899; OR, 1.37; 95% CI, 1.12--1.69; P=0.002 ([Fig. 2B](#f2-br-0-0-632){ref-type="fig"} and [Table III](#tIII-br-0-0-632){ref-type="table"}); \*0502, case vs. control: I^2^=24.9%; P-value of heterogeneity=0.239; OR, 1.50; 95% CI, 1.02--2.20; P=0.04 ([Fig. 2C](#f2-br-0-0-632){ref-type="fig"} and [Table III](#tIII-br-0-0-632){ref-type="table"})\], which were associated with increased risk of CHB. Similar significant results were observed and acquired in the following *HLA-DQB1* loci \[\*0303, case vs. control: I^2^=0%; P-value of heterogeneity=0.986; OR, 0.77; 95% CI, 0.62--0.95; P=0.017 ([Fig. 2D](#f2-br-0-0-632){ref-type="fig"} and [Table III](#tIII-br-0-0-632){ref-type="table"}); \*0604, case vs. control: I^2^=0%; P-value of heterogeneity=0.594; OR, 0.38; 95% CI, 0.20--0.74; P=0.003 ([Fig. 2E](#f2-br-0-0-632){ref-type="fig"} and [Table III](#tIII-br-0-0-632){ref-type="table"})\], which were associated with a decreased risk of CHB. No significant association was observed for the other *HLA-DQB1* family loci ([Table III](#tIII-br-0-0-632){ref-type="table"}).

### Sensitivity analysis

Sensitivity analysis was performed by removing one study at a time to detect the source of heterogeneity. There was no evident heterogeneity in all the *HLA-DQB1* family loci. Additionally, there was no valid evidence to support that any study independently influenced the combined OR, which indicated that the overall results of this study are robust and convincing, as shown in the plots for sensitivity analysis ([Fig. 3](#f3-br-0-0-632){ref-type="fig"}).

### Publication bias

Begg\'s funnel plots and Egger\'s regression plots were used to detect the publication bias of all the *HLA-DQB1* loci. As illustrated in [Fig. 4](#f4-br-0-0-632){ref-type="fig"}, the funnel plots did not show any evidence of significant asymmetry and suggested that no publication bias existed \[\*0201, Z=0.6, P=0.548 ([Fig. 4A](#f4-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0301, Z=1.5, P=0.133 ([Fig. 4B](#f4-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0502, Z=1.5, P=0.133 ([Fig. 4C](#f4-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0303, Z=0, P=1 ([Fig. 4D](#f4-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0604, Z=0.24, P=0.86 ([Fig. 4E](#f4-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"})\]. Egger\'s test also indicated that there was no statistically significant publication bias \[\*0201, T=−0.66, P=0.54 ([Fig. 5A](#f5-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0301, T=0.63, P=0.554 ([Fig. 5B](#f5-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0502, T=1.18, P=0.291 ([Fig. 5C](#f5-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0303, T=−1.03, P=0.349 ([Fig. 5D](#f5-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"}); \*0604, T=0.01, P=0.996 ([Fig. 5E](#f5-br-0-0-632){ref-type="fig"} and [Table IV](#tIV-br-0-0-632){ref-type="table"})\].

Discussion
==========

To the best of our knowledge, this is the first study investigating the association of *HLA-DQB1* alleles with CHB. Numerous studies have suggested the associations of *HLA* gene polymorphisms with inflammatory diseases and autoimmune diseases, such as HBV infection ([@b32-br-0-0-632],[@b47-br-0-0-632]), hepatitis C virus infection ([@b48-br-0-0-632],[@b49-br-0-0-632]), systemic lupus erythematosus ([@b50-br-0-0-632]) and rheumatoid arthritis ([@b51-br-0-0-632]). However, the majority of these studies focus on the correlation between the HLA antigen and CHB based on a small sample size and HLA serotyping that has limited resolution; therefore, those results may be inaccurate and inconsistent for the distribution of numerous *HLA-DQB1* loci. Along with the development of genotyping methods, *HLA*-genotyping is becoming more precise in the identification of the *HLA-DQB1* loci, and more accurate in the identification of the peptide-binding site of MHC II molecules. Therefore, HLA genotyping methods are being used more frequently in the study of immunogenetics.

Recent studies on the correlation between *HLA-DQB1* polymorphisms and CHB have been inconsistent and inconclusive. Jiang *et al* ([@b34-br-0-0-632]) reported that *HLA-DQB1*\*0301 are closely associated with susceptibility to CHB, while other *HLA-DQB1* alleles are not. Thus, it is plausible that the *HLA-DQB1*\*0301 allele may be a risk factor for the development of CHB (OR, 3.9). Park *et al* ([@b43-br-0-0-632]) insisted that *HLA-DQB1*\*0402 and DQB1\*0604 alleles have a certain protective effect on the occurrence of CHB (OR, 0.3; and OR, 0.1, respectively). Therefore, these alleles may be considered as good prognostic factors. Liu and Cheng ([@b45-br-0-0-632]) observed that the *HLA-DQB1*\*0201 and *DQB1*\*0601 alleles have significant susceptible effect on chronic HBV infection (OR, 2.93; and OR, 2.07, respectively). However, Xi-Lin *et al* ([@b44-br-0-0-632]) identified that the *HLA-DQB1*\*0303 and *DQB1*\*0503 alleles are independently resistant genetic factors to CHB (OR, 0.65; and OR, 0.35, respectively). Zhu *et al* ([@b46-br-0-0-632]) further observed that the *HLA-DQB1*\*0502 allele is significantly associated with the clinical outcome of HBV infection (OR, 18) and is a host genetic risk factor for HBV infection.

The present study showed that five specific *HLA-DQB1* loci are associated with an increased or decreased risk of CHB. Among the 13 specific *HLA-DQB1* alleles, *DQB1*\*0201, *DQB1*\*0301 and *DQB1*\*0502 were significantly associated with the increased risk of CHB. The pooled OR was 1.29 (95% CI, 1.02--1.64; P=0.0301), 1.37 (95% CI, 1.12--1.69; P=0.002) and 1.50 (95% CI, 1.02--2.20; P=0.04), respectively. However, *DQB1*\*0303 and *DQB1*\*0604 were significantly associated with a decreased risk of CHB. The pooled OR was 0.77 (95% CI, 0.62--0.95; P=0.017) and 0.38 (95% CI, 0.20--0.74; P=0.003), respectively. No significant association was observed for the other *HLA-DQB1* family alleles. The overall results indicate that *HLA-DQB1*\*0201, *HLA-DQB1*\*0301 and *HLA-DQB1*\*0502 alleles may have a significantly higher risk for CHB, while *HLA-DQB1*\*0303 and *HLA-DQB1*\*0604 may have a significantly protective effect for CHB.

The study by Zhang *et al* ([@b35-br-0-0-632]) suggested that *HLA-DQB1*\*0303 is a resistance gene of CHB in Xinjiang Uygur, while *HLA-DQB1*\*0301 is associated with continuous infection of HBV. The *HLA-DQB1*\*0201 distribution frequency in the low copy group was significantly higher than that of the high copy group (OR, 1.939; P\<0.05), and thus assumed that *DQB1*\*0201 may contribute to the clearance of HBV ([@b35-br-0-0-632]). In addition, Li *et al* ([@b52-br-0-0-632]) reported that the *HLA-DQB1*\*0501, *HLA-DQB1*\*0601 and *HLA-DQB1*\*0602 alleles are associated with significantly increased immunological responses to the hepatitis B vaccine in healthy people (OR, 1.85; OR, 2.35; and OR, 2.34, respectively), while *HLA-DQB1*\*0201 is adverse (OR, 0.27). The mechanisms underlying these effects on CHB are not fully elucidated, but larger-scale studies provide a promise of further confirmation. Jiang *et al* ([@b53-br-0-0-632]) identified five novel susceptibility loci for CHB using a GWAS with 2,514 CHB cases and 1,130 normal controls from eastern China, and four of them are located in the human leukocyte antigen (HLA) region at 6p21.3. Additionally, the study validated seven previously reported CHB susceptibility loci, including rs2856718 at *HLA-DQB1*, rs7453920 at HLA-DQB2, rs3077 at HLA-DPA1, rs9277535 at HLA-DPA2, rs3130542 at HLA-C, rs1419881 at TCF19, and rs652888 at EHMT2 ([@b53-br-0-0-632]). All are located in the HLA region.

CHB development is preceded by acute inflammation and immune responses. Whether antigen-presenting cells are able to identify HBV antigens may be critical for the development of CHB. The correlation of specific *HLA-DQB1* alleles with resistance or susceptibility to CHB is possibly attributed to a direct effect of *HLA-DQB1* molecule as an antigen-presenting unit or possibly owing to a neighboring-related gene ([@b53-br-0-0-632]). We assume that the host immune response status of the patients with CHB and carrying *HLA-DQB1* polymorphisms are changed. T-cells are often activated under certain conditions such as infection, depression and fatigue. Accompanied by the removal of HBV, liver damage was triggered and a range of clinical symptoms occurred such as fever, anorexia, abnormally elevated aminotransferases and icterus, inducing the formation of CHB. With regards to the *HLA-DQB1* loci, it may be plausible that HLA molecule mediates the function of host antigen-presenting cells and induces cytotoxic T-lymphocyte responses.

However, due to the potential heterogeneity of HBV, the results of the present study should be explained with caution. These retrospective studies are more prone to bias than prospective randomized clinical trial (RCT) studies. The information of CHB patients complicated by HCC were not specially extracted and analyzed. The association of *HLA-DQB1* loci with HCV infection was not included in the meta-analysis. The overall sample size was relatively small due to the limited number of original studies.

In conclusion, the present meta-analysis suggests that *HLA-DQB1*\*0201, *DQB1*\*0301 and *DQB1*\*0502 are risk factors for CHB, while *HLA-DQB1*\*0303 and *DQB1*\*0604 are protective factors. These results are compatible with the published studies regarding the correlation between *HLA-DQB1* loci and other inflammatory disorders. Future large scale studies of *HLA-DQB1* should be used to provide strong evidence for a genetic contribution to CHB.
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###### 

Characteristics of the studies included in the meta-analysis.

  First author (year)     Region   Ethnicity   Design   Genotyping      Case (n)   Control (n)   Refs.
  ----------------------- -------- ----------- -------- --------------- ---------- ------------- ---------------------
  Jiang *et al* (2003)    China    Asian       PB       PCR/SSP           52       106           ([@b34-br-0-0-632])
  Park *et al* (2003)     Korean   Asian       PB       PCR/RFLP/SSCP   135        100           ([@b43-br-0-0-632])
  Xi-Lin *et al* (2006)   China    Asian       HB       PCR/SSP         139        134           ([@b44-br-0-0-632])
  Liu and Cheng (2007)    China    Asian       PB       PCR/SSP         168        100           ([@b45-br-0-0-632])
  Zhu *et al* (2007)      China    Asian       HB       PCR/SSP         151        133           ([@b46-br-0-0-632])
  Zhang *et al* (2015)    China    Asian       HB       PCR/SSP         110        100           ([@b35-br-0-0-632])
  Li *et al* (2015)       China    Asian       HB       PCR/SSP           60         58          ([@b37-br-0-0-632])

HB, hospital-based; PB, population-based; PCR, polymerase chain reaction; SSP, sequence-specific primer; SSCP, single-strand conformation polymorphism; RFLP, restriction fragment length polymorphism.

###### 

Distribution of the *HLA-DQB1* polymorphisms in chronic hepatitis B.

                          *HLA-DQB1* loci                                                               
  ----------------------- ----------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---------------------
  Jiang *et al* (2003)                                                                                  ([@b34-br-0-0-632])
    Case, n               10                37   6    15   5    1    3    7    2    7    4    2    2    
    Control, n            23                40   14   35   11   2    9    20   6    20   12   5    7    
  Park *et al* (2003)                                                                                   ([@b43-br-0-0-632])
    Case, n               31                43   27   23   22   5    12   9    17   31   27   2    4    
    Control, n            13                26   18   24   9    11   17   3    11   12   18   5    14   
  Xi-Lin *et al* (2006)                                                                                 ([@b44-br-0-0-632])
    Case, n               48                71   10   58   8    NA   12   17   8    24   21   1    0    
    Control, n            45                55   9    74   10   NA   9    11   14   25   13   0    3    
  Liu and Cheng (2007)                                                                                  ([@b45-br-0-0-632])
    Case, n               63                10   14   14   9    5    7    9    16   45   67   7    7    
    Control, n            17                5    8    12   10   5    2    3    8    15   52   3    7    
  Zhu *et al* (2007)                                                                                    ([@b46-br-0-0-632])
    Case, n               51                79   12   61   8    NA   15   18   NA   26   22   NA   NA   
    Control, n            38                56   20   61   10   NA   18   3    NA   15   25   NA   NA   
  Zhang *et al* (2015)                                                                                  ([@b35-br-0-0-632])
    Case, n               20                30   9    22   3    NA   5    7    NA   NA   10   1    1    
    Control, n            11                17   8    31   4    NA   6    5    NA   NA   9    2    1    
  Li *et al* (2015)                                                                                     ([@b37-br-0-0-632])
    Case, n               3                 42   2    13   6    1    6    7    4    11   8    1    NA   
    Control, n            8                 27   8    17   3    0    6    8    3    16   7    1    NA   

NA, not available; HLA, human leukocyte antigen.

###### 

Results of Q-test and I^2^ test for *HLA-DQB1* polymorphisms in chronic hepatitis B.

  *HLA-DQB1* loci   Q-value   I^2^, %   P-value   OR (95% CI)         Pooled P-value
  ----------------- --------- --------- --------- ------------------- ----------------
  0201                9.45    36.5      0.150     1.29 (1.02--1.64)   0.031
  0301                2.21      0.0     0.899     1.37 (1.12--1.69)   0.002
  0302                5.12      0.0     0.523     0.84 (0.60--1.16)   0.290
  0303                0.98      0.0     0.986     0.77 (0.62--0.95)   0.017
  0401              53.23     88.7      \<0.001   0.47 (0.15--1.43)   0.182
  0402                2.05      0.0     0.562     0.53 (0.25--1.10)   0.088
  0501                3.81      0.0     0.702     0.82 (0.57--1.19)   0.293
  0502                7.98    24.9      0.239     1.50 (1.02--2.20)   0.040
  0503                2.17      0.0     0.704     0.93 (0.60--1.45)   0.741
  0601                7.39    32.3      0.193     1.24 (0.93--1.64)   0.138
  0602                3.67      0.0     0.721     0.93 (0.72--1.20)   0.565
  0603                2.84      0.0     0.725     0.79 (0.38--1.66)   0.536
  0604                2.78      0.0     0.594     0.38 (0.20--0.74)   0.003

OR, odds ratio; CI, confidence interval, HLA, human leukocyte antigen.

###### 

Results of Beggs test and Eggers test for *HLA-DQB1* polymorphisms in chronic hepatitis B.

         Beggs test   Eggers test           
  ------ ------------ ------------- ------- -------
  0201   0.60         0.548         −0.66   0.540
  0301   1.50         0.133         0.63    0.554
  0302   1.50         0.133         −1.24   0.270
  0303   \<0.01       1.000         −1.03   0.349
  0401   \<0.01       1.000         −0.25   0.811
  0402   1.70         0.089         3.57    0.070
  0501   0.90         0.368         1.30    0.249
  0502   1.50         0.133         1.18    0.291
  0503   0.73         0.462         −0.14   0.897
  0601   0.38         0.707         −1.24   0.282
  0602   0.60         0.548         0.80    0.459
  0603   0.38         0.707         0.22    0.836
  0604   0.24         0.806         0.01    0.996

HLA, human leukocyte antigen.
